Peptides Are Everywhere—But Who’s Actually Qualified To Give Advice?

Peptides are everywhere—from longevity clinics to social media. But not everyone is qualified to give advice. Here’s what to know before you trust the trend.

Google’s Weirdest AI Dataset Yet: Garbage

The search giant had previously created a machine learning data set out of food scraps from its kitchens. Now it’s partnering with Mill, which makes a high-tech trash bin, to use that data to train its AI algorithms.

SpaceX’s IPO Could Leave Tesla Eating Rocket Dust

Tesla shares could be overshadowed by the aerospace company’s record-breaking $1.75 billion public offering and what some investors see as more “sizzle.”

Using AI To Personalize Healthcare–Without Losing Patient Trust

In this week’s edition of InnovationRx, we look at the opportunities and challenges of using AI to personalize healthcare and speed up clinical trials, the future of genetic medicine, another big Lilly acquisition, and more.

Warming Oceans, A Hot Year And ‘Elite’ Beliefs

This week’s Current Climate newsletter also looks at whether urbanists should embrace robotaxis and how the Middle East war may impact the renewable energy transition

European tech weekly recap: More than 75 tech funding deals worth over €1.9B

Last week, we tracked more than 75 tech funding deals worth over €1.9 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe.Haberin devamını okumak için tıklayın…

The Newest Trend In Tech Embraces Femininity And Fun

The female content creators engaging viewers, experimenting with design and stepping away from optimization to develop technology that amplifies joy.

OpenAI Wants Its AI To Help Scientists Make Discoveries Faster

Solving a century-old mystery about rubber. The space economy keeps booming. The physics of stir fry. All that and more in this week’s edition of The Prototype.

This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors to buy stalled drugs and use AI to stress test them …

This $1.5 Billion AI Startup Steps In When Software Breaks

After watching engineers burn out from fixing late-night outages, Resolve AI CEO Spiros Xanthos is developing AI systems to ease the burden of being on call, backed by a new $40 million funding round.